Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 1019-6439 Online ISSN: 1791-2423
Journal Cover
October-2017 Volume 51 Issue 4

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
October-2017 Volume 51 Issue 4

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9

  • Authors:
    • Eun Ho Kim
    • Mi-Sook Kim
    • Kyung-Hee Lee
    • Sei Sai
    • Youn Kyoung Jeong
    • Jae-Soo Koh
    • Chang-Bae Kong
  • View Affiliations / Copyright

    Affiliations: Division of Heavy Ion Clinical Research, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea, Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea, Department of Orthopaedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea, Department of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan, Research Center for Radiotherapy, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea, Department of Pathology, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea
    Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 1124-1134
    |
    Published online on: August 25, 2017
       https://doi.org/10.3892/ijo.2017.4102
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Osteosarcoma (OS) is a malignant tumor of the bone derived from primitive transformed cells of the mesenchymal origin. Local low-linear energy transfer (LET) radiotherapy has limited benefits on OS owing to its radioresistance. Thus, this study aimed to investigate the effects of high-LET radiation on human OS. Therefore, the human OS cell lines, U2O2 and KHOS/NP, were examined in vitro, or an orthotopic mouse xenograft model was studied in vivo after treatment with low-LET (gamma-ray) and high-LET (neutron) radiation. Notably, OS cells were significantly more sensitive to high-LET radiation in vitro and in the orthotopic xenograft tumor model. Specifically, neutron radiation treatment increased the relative percentage of apoptotic sub-G1 phase cells via caspase-3/9 activation; increased intracellular reactive oxygen species, autophagy, and DNA damage; and decreased invasion and migration. Similarly, the mean size of gamma-irradiated (8 Gy) orthotopic KHOS/NP OS was 195 mm3 at 6 weeks after gamma-irradiation (8 Gy), but it was only 150 mm3 in mice treated with high-LET neutron radiotherapy. Significantly, our results provide a rationale for the use of high-LET radiotherapy to treat patients with OS.

Introduction

Osteosarcomas (OSs) are highly aggressive primary bone tumors of osteoblastic origin that predominantly affect children and young adults (1). Early treatment paradigms in the 1960s entailed aggressive local control with amputation. More recently, a multidisciplinary treatment approach has enhanced both the overall survival and preservation of the organ/limb function (2). Ionizing radiation (IR) therapy is a facet of the modern approach to treat OS (3–6); however, recent reports have emphasized the limited therapeutic efficacy of local low-LET (gamma-radiation) radiotherapy for the treatment of OS, as well as an increased risk of pulmonary metastasis (5–8). Consequently, conventional therapies are unable to prevent metastatic progression in 30–40% of the patients with OS (9). To generate a more effective and comprehensive treatment methodology, utilization of high-LET radiation might be necessary to treat OS that has become resistant to low-LET radiation. High-LET radiation has several advantages for treating radio-resistant human cancers because of its higher relative biological effectiveness (RBE), lower oxygen enhancement ratio (OER), and decreased cell cycle-dependent radiosensitivity. In addition, because cells are less likely to repair radiation-induced damage, charged particle radiation may exert highly lethal effects on radioresistant tumors as compared to conventional low-LET X-ray or gamma-ray irradiations (10–13).

As compared to conventional approaches, carbon ion high-LET radiotherapy is highly efficacious in treating deep-seated malignant OSs (14,15). In addition, boron neutron capture therapy (BNCT) has been used to successfully treat a patient with recurrent radiation-induced OS (16). However, the molecular mechanisms underlying carbon ion- or neutron-induced OS cytotoxicity are largely unknown. Therefore, this study investigated the therapeutic effects of high-LET neutron radiation on OS in vitro and in vivo.

Materials and methods

Antibodies and chemicals

Anti-p53 and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-cleaved PARP, caspase-3, caspase-9, cleaved caspase-3, cleaved caspase-9, anti-LC3, anti-ATM, anti-p95/NBS1, anti-Ku70, anti-Ku80, anti-DNA-PKcs, and anti-ERCC1 were purchased from Cell Signaling Technology (Danvers, MA, USA), and anti-γ-H2AX was obtained from Millipore (Billerica, MA, USA).

Cell culture

The OS cell lines, U2O2 and KHOS/NP [American Type Culture Collection (ATCC), Rockville, MD, USA], were maintained in α minimum essential medium (α-MEM; Gibco Life Technologies, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco Life Technologies) and 1% (v/v) penicillin-streptomycin solution (Gibco Life Technologies).

Irradiation

Cells were cultured in 60- or 100-mm dishes until 70–80% confluence at 37°C in a humidified atmosphere of 5% CO2. Irradiations were performed using a 137Cs gamma-ray source (Atomic Energy of Canada, Ltd., Ontario, Canada) at a dose rate of 3.81 Gy/min. Fast neutrons (9.8 MeV, 30–40 keV/μm) were produced by the bombardment of proton on beryllium 9Be(p,n)10B as a nuclear reaction in the cyclotron (MC-50; Scanditronix, Uppsala, Sweden). Paired ionization chambers were used to measure the absorbed dose and dose distribution of fast neutron beams or gamma-rays (17). Dosimetric measurements were done before in vitro study to calculate neutron dose using RBE, 2.2, which has been used for neutron therapy in our institute and it showed cell killing efficacy equivalent to that of gamma-ray as determined by clonogenic assay (18).

Colony-forming assay

Cells (500–1000) were seeded into 60-mm dishes in triplicate and stained with 0.4% crystal violet (Sigma, St. Louis, MO, USA) after 14–20 days to determine plating efficiency (PE), defined as the percentage of seeded cells that formed colonies under the specific culture conditions. The surviving fraction was expressed as a function of irradiation as follows: survival fraction = colonies counted / (cells seeded × PE/100). The plating efficiencies of U2O2 and KHOS/NP cells were 0.48±0.18 and 0.34±0.02, respectively. RBE is defined as the ratio of the doses of the two radiations required to cause the effect to the same degree. To evaluate the RBE, the ratio of the doses of the two types of radiations required for similar effect at a survival fraction of 50% was determined. RBE was evaluated and calculated as the dose (Gy) for gamma-ray radiation divided by the dose for neutron radiation that yielded a surviving fraction of 50% (D50).

Water-soluble tetrazolium (WST-1) assay

For the cytotoxicity assay, cells were seeded in 96-well culture plastic plates at a density of 1×103 cells per well. Each well was exposed to radiation at varying doses (0–5 Gy) and the cells were incubated for 72 h, followed by application of the water-soluble tetrazolium (WST)-1 cytotoxicity assay reagent (Roche Diagnostics, Laval, Quebec, Canada) according to the manufacturer's recommendations. Cell viability was assessed by determining the A450 nm of the cell culture media after addition of WST-1 for 2 h. The results are reported as a percentage of the optical density of the untreated control cells, which was designated as 100% cell viability. Percentage of cytotoxicity was calculated as (1-Aexp/Acon) ×100, where Aexp and Acontrol are the absorbance values of the experimental IR-treated and control untreated cells, respectively.

Analysis of cell cycle progression

Cells were seeded in 60-mm dishes at 60% confluency. After 24 h, cells were trypsinized, harvested, and fixed in 1 ml 70% cold ethanol in test tubes and then incubated at 4°C overnight. The fixed cells were centrifuged at 2,000 rpm for 3 min, and the pellets were resuspended in 500 μl propidium iodine (10 μg/ml) containing 300 μg/ml RNase (Sigma). Cell cycle distribution was determined using 10,000 cells with CellQuest™ software using a FACSCaliber flow cytometer (Becton Dickinson, San Jose, CA, USA).

Detection of apoptotic cells by Annexin V staining

Cells were irradiated and subsequently incubated for 48 h. Cells (1×106 cells/ml) were then washed with ice-cold PBS, trypsinized, and resuspended in 1X binding buffer [10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2]. Aliquots (100 μl) of the cell solution were mixed with 5 μl Annexin V/fluorescein isothiocyanate (FITC) (BD Biosciences, Franklin Lakes, NJ, USA) and 10 μl propidium iodide (PI) stock solution (50 μg/ml in PBS) by gentle vortexing, followed by 15-min incubation at room temperature under dark conditions. Next, 400 μl 1X binding buffer was added to each sample, and the samples were analyzed on a FACScan™ flow cytometer (BD Biosciences). A minimum of 10,000 cells were counted for each sample, and data were analyzed using CellQuest™ software (BD Biosciences).

Western blotting

Irradiated OS cells were cultured and then lysed with RIPA buffer. Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with 1% (v/v) nonfat dry milk in Tris-buffered saline with 0.05% Tween-20 and incubated with the indicated primary and secondary antibodies (1:1,000 and 1:5,000 dilution, respectively). Immunoreactive protein bands were visualized by enhanced chemiluminescence (Amersham Biosciences, Little Chalfont, UK).

Caspase activity

Caspase-3 and -9 activities were determined by using detection kits (R&D Systems, Minneapolis, MN, USA). The assay is based on spectrophotometric detection of the chromophore p-nitroanilide (pNA) after cleavage from the labeled substrates of DEVD-pNA (for caspase-3) and LEHD-pNA (for caspase-9). The pNA light emission can be quantified using a spectrophotometer or microtiter plate reader at 405 nm. Comparison of the pNA absorbance of apoptotic and control samples allows determination of the fold increase in caspase activity.

Intracellular reactive oxygen species detection

Reactive oxygen species (ROS) were monitored using the fluorescent ROS indicator, C2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA; 5 μM; Molecular Probes, Eugene, OR, USA). Cell-associated fluorescence was detected by FACS using a FACSort™ flow cytometer with CellQuest software (BD Biosciences).

Quantitative detection of acid vesicular organelles by acridine orange staining

Autophagy is the process of sequestrating cytoplasmic proteins and organelles into the lysosomal component and is characterized by development of acid vesicular organelles (AVOs). To detect and quantify AVOs in IR-treated cells, we performed vital staining with acridine orange (Polysciences, Warrington, PA, USA) as previously described. U2OS and KHOS/NP cells were stained with 1.0 μg/ml acridine orange for 15 min at room temperature and processed for flow cytometry using the FACScan cytometer and analyzed with CellQuest software (Becton Dickinson).

Immunocytochemistry

Immunocytochemistry was performed to determine the nuclear distribution of γ-H2AX in individual cells. Cells were grown on chambered slides for 1 day prior to IR. After exposure, cells were irradiated and incubated for 1 or 24 h. All treatments were performed while cells remained attached to the slides, followed by fixation with 4% (w/v) paraformaldehyde and permeabilization with 0.5% (v/v) Triton™ X-100 in PBS. Detection was performed after the slides were blocked in 10% (v/v) FBS/1% (v/v) bovine serum albumin for 1 h, followed by incubation with a 1:1,000 dilution of FITC-labeled mouse monoclonal antibody against γ-H2AX (Millipore).

Wound healing (scratch) assay

Human OS cells were seeded onto 6-well plates (Corning) at a density of 2.5×104 cells/well, 3 ml medium was added, and the cells were irradiated. On day 2, the monolayers were mechanically disrupted with a sterile 200-μl pipette tip. The assay was performed in duplicates, and wells were photographed every 48 h prior to staining with 0.2% (w/v) crystal violet. Cell migration was monitored using an Eclipse Ti microscope with a DS-Fi1 camera (Nikon, Tokyo, Japan). The cells were counted using ImageJ (US National Institutes of Health, Bethesda, MD, USA).

Transwell chamber assay

The in vitro invasive ability of OS cells was measured using transwell chambers according to the manufacturer's protocol. Briefly, cells were seeded onto the membrane of the upper chamber of the transwell at a density of 4×105/ml in 150 μl medium and were left untreated or irradiated with IR for 24 h. The medium in the upper chamber was serum-free, whereas the medium in the lower chamber contained 10% (v/v) FBS as a source of chemoattractants. Cells that passed through the Matrigel®-coated membrane were stained with cell stain solution containing crystal violet supplied in the Transwell chamber assay (Chemicon; Millipore) and photographed after 24 h of incubation.

Orthotopic model and histological analysis

Twelve 4-week-old female BALB/c nude mice (average body weight, 12.1 g; range 11.3–13.1 g) were obtained from Orient Bio Inc. (Seoul, Korea) and quarantined for 1 week prior to experimentation. KHOS/NP orthotopic tumors were established as previously described (19).

Cells were implanted into the tibias of mice anesthetized by intraperitoneal injection of Zoletil (Virbac, Carros, France) and Roumpun (Bayer Korea, Seoul, Korea). Briefly, the left tibia was wiped with 70% (v/v) ethanol and an 18-gauge needle was inserted through the tibial plateau with the knee flexed. Then, 1×105 KHOS/NP cells in 10 μl PBS were injected into the marrow space of the proximal tibia with a 26-gauge needle coupled with a Hamilton syringe. Two weeks after OS cell inoculation, mice were randomly assigned into IR or control groups (n=4/group). IR was given as a single dose of 8 Gy of low-LET gamma-ray or high-LET neutron radiotherapy. Animals were sacrificed 6 weeks after inoculation by CO2 asphyxiation. Tumor length (L) and width (W) were measured with calipers after their sacrifice and used to calculate tumor volume as follows: volume = (L × W2)/2. All experimental protocols were approved by the Institutional Animal Care and Use Committee of the Korea Institute of Radiological and Medical Sciences. Histological analysis was performed using hematoxylin and eosin (H&E)-stained paraffin sections (20,21).

Statistical analysis

All analyses were performed by Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

U2OS and KHOS/NP clonogenicity following gamma-ray or neutron irradiation

U2O2 and KHOS/NP OS clonogenic survival decreased as a function of exposure to gamma-ray or neutron irradiation dose (Fig. 1). The results of the colony-forming assay of irradiated KHOS/NP cells are shown in Fig. 1A in the form of survival curves. The surviving fraction (S/S0) data for irradiated OS cells were fitted with the linear quadratic dose (D)-dependent relation given by S/S0 = exp − (αD + βD2), where α and β are constants. The fitted values of α and β for irradiated KHOS/NP cells are provided in Table I. RBE depends on the dose and the biological endpoints. The average endpoint D50 for U2O2 and KHOS/NP cells was 0.81 and 3.11 Gy for gamma-irradiation, and 0.45 and 2.01 Gy for neutron irradiation, respectively (Table II). Similarly, the dose ratio required for attaining D50 with gamma-ray or neutron irradiation is extracted from Fig. 1A and summarized in Table II. The values from the fitted curves suggest that as compared to that of gamma-ray irradiation, neutron irradiation was far more effective in reducing the survival fraction. Additionally, U2OS cells showed more radiosensitive than KHOS/NP cells. Therefore, the RBE values of neutron irradiation relative to gamma-ray irradiation were 1.80 and 1.55, respectively, indicating that the neutron beam exerts more effective cell killing effects compared to the gamma-ray irradiation. The two OS cell lines were also subjected to cell viability analysis by WST-1 assay after either form of irradiation (Fig. 1B), which verified that neutron irradiation had a more potent radiosensitizing effect.

Figure 1

The radiation effects of high LET on OS cells. (A) Radiosensitivity of U2O2 and KHOS/NP cell lines after various doses of gamma-ray and neutron radiation was measured by colony forming assay. Asterisks (*) indicate values that are statistically significant in comparison to radiation-treated cells. Values represent means of 3 experiments ± SD; *P<0.05. (B) Cell viability of two OS cell lines treated with gamma-ray and neutron for 72 h was measured by the WST-1 assay. Values represent means of 3 experiments ± SD; *P<0.05.

Table I

Fitting parameters α and β for survival assay data.

Table I

Fitting parameters α and β for survival assay data.

Cell typeRadiation typeα (Gy−1)β (Gy−1)
U2OSgamma-ray0.182±1.2600.042±0.447
Neutron3.552±1.2580.416±0.445
KHOS/NPgamma-ray0.097±0.7280.148±0.162
Neutron0.107±0.7290.212±0.164

Table II

Radiation dose required for 50% cytotoxicity and relative biological effectiveness (RBE) values (data extracted from Fig. 1).

Table II

Radiation dose required for 50% cytotoxicity and relative biological effectiveness (RBE) values (data extracted from Fig. 1).

Cell typeRadiation typeD50RBE
U2OSgamma-ray0.811.80
Neutron0.45
KHOS/NPgamma-ray3.111.55
Neutron2.01
Effect of low- or high-LET IR-induced apoptosis and cell cycle

We next analyzed the effects of gamma-ray and neutron irradiation on cell cycle progression using flow cytometry to assess the relative changes in apoptotic sub-G1 cells. Notably, neutron irradiation resulted in a higher overall increase in sub-G1 cells than that in gamma-ray-treated counterparts in a time-dependent manner (Fig. 2A). To determine the fraction of OS cells induced to undergo apoptosis by the radiation treatment, we detected apoptosis by Annexin V and PI staining. Notably, 48 h treatment with neutron increased the percentage of early apoptotic cells as compared to that after treatment with gamma-ray in the two OS cell lines (Fig. 2B). Cleavage-induced caspase activation is a defining characteristic of apoptotic cell death (22). Therefore, we examined caspase-3 and caspase-9 expression and cleavage by western blotting. As shown in Fig. 2C, cell irradiation resulted in increased caspase-3 and -9 expression in OS cells, with a more potent effect observed with neutron radiation. Caspase-3 activation leads to PARP-1 cleavage (23). As expected, western blot analysis showed a marked increase in cleaved PARP-1 level up to 48 h after exposure, and a more substantial effect was observed with neutron radiation (Fig. 2C). We measured radiation-induced activation of caspase-3 and -9 protease activities. As shown in Fig. 2D, neutron radiation significantly enhanced caspase-3 and -9 as compared to that by gamma-ray radiation. Annexin V staining and caspase activation indicated that neutron irradiation-induced cell death is dependent on apoptosis induction. To investigate the relationship between ROS production and radiation-induced apoptosis, the effects of ROS production on OS cells were examined. These results revealed elevated ROS production in cells treated with high-LET radiation as compared to that in cells treated with low-LET radiation (Fig. 2E).

Figure 2

Effects of radiation on apoptosis and cell cycle in OS cells. (A) U2O2 and KHOS/NP cells were treated with 5 Gy gamma-ray and neutron radiation for indicated time points. The cell cycle distribution of sub-G1 was analyzed quantitatively. (B) After 48 h of treatment, U2O2 and KHOS/NP cells were subjected to Annexin V and PI staining and analyzed by flow cytometry. (C) Cell lysates (30 μg) were immunoblotted (IB) with indicated antibodies. (D) Caspase activities in OS were determined (see Materials and methods). Data are expressed as % of control and are means ± SE for 3 experiments. (E) ROS concentration measured at 48 h after treatment with radiation. *P<0.05.

Effect of radiation-induced autophagy on OS cells

Autophagy was determined after irradiation by counting AVO-containing cells at given time-points (Fig. 3A). Higher increase in autophagy after neutron irradiation was demonstrated in the two cell lines. The expression of LC3 protein, which is known to be a standard indicator of autophagy, was assessed. Among two separate bands observed on western blot (an upper one of 18 kDa for LC3-bI and a lower one of 16 kDa for LC3-bII), the lower band representing fusion of the autophagosome to lysosome increased with increasing time after neutron irradiation (Fig. 3B).

Figure 3

Analysis of autophagy after radiation in OS cells. (A) U2O2 and KHOS/NP cells were irradiated with radiation and then incubated for the indicated times. To measure acidic vesicular organelle (AVO), which is indicative of autophagy formation, cells were stained with acridine orange and analyzed quantitatively by flow cytometry. Values represent the means of 3 experiments ± SD; *P<0.05, **P<0.001. (B) Cell lysates (30 μg) were immunoblotted (IB) with indicated antibodies.

Effect of low- or high-LET IR on DNA damage

To explore the involvement of cellular DNA repair in high-LET radiation-induced OS cytotoxicity, we analyzed the abundance of the damage-response protein, H2AX, by immunocytochemistry and western blotting. The number of γH2AX foci was initially increased 1 h after irradiation with either gamma-ray or neutron beams, but then substantially declined after 24 h. The two OS cell lines treated with neutron radiation exhibited damaged DNA foci, which appeared 1 h after treatment exposure and were retained even 24 h after exposure; therefore, the effect was greater with neutron radiation than with gamma-ray irradiation (Fig. 4A and B). Moreover, neutron-irradiated cells exhibited higher degree of IR-induced γ-H2AX staining, indicative of increased DNA damage (Fig. 4A and B). To investigate whether reduced double-stranded break (DSB) repair activity detected in IR-treated cells was due to the suppression of DSB repair-related proteins, the effect of IR treatment on the expression of key proteins in the homologous recombination (HR) and non-homologous end-joining (NHEJ) pathways was examined. The relative abundance of DNA damage repair-associated proteins in OS cells under various treatment conditions is shown in Fig. 4C. The proteins Ku70, Ku80, DNA-PKcs, NBS1, and ERCC1 were downregulated 24 h after neutron irradiation in U2OS cells. However, Ku70, NBS1, and ERCC1 were downregulated 24 h after neutron irradiation in KHOS/NP cells. These results suggest that neutron irradiation inhibits the expression of both HR- and NHEJ-related proteins, inhibiting the repair of IR-induced DSBs, depending upon the cell lines.

Figure 4

The effects on the DNA damage response in irradiated OS cells. (A and B) Immunocytochemistry for phosphorylated H2AX, a marker of the DNA damage response, in U2OS and KHOS/NP cells exposed to radiation at 1 and 24 h after irradiation. Values represent the means of 3 experiments ± SD; *P<0.05, **P<0.001. (C) Cell lysates (30 μg) were immunoblotted (IB) with indicated antibodies.

Effect of IR on cell motility and cell invasion

Next, the effects of gamma-ray and neutron irradiation on the migratory abilities of OS cells were estimated using a scratch assay. Remarkably, compared to gamma-ray radiation, neutron radiation significantly inhibited cell migration (Fig. 5A). Matrigel invasion assay was also performed to examine the effect of IR on tumor cell invasiveness in OS cell lines, and it was found that neutron irradiation effectively inhibited tumor cell invasion (Fig. 5B).

Figure 5

The effect of treatment with radiation on the invasion and migration of OS cells. (A) U2OS and KHOS/NP cells were scraped with 200-μl pipette tips for the scratch assay and then treated with 5 Gy gamma-ray and neutron radiation. After incubation for 24 h, the number of cells that migrated across the wound was counted. Each assay was photographed, distances between the migrating cell edges were quantified, and percentage cell migration was calculated. Values represent the means of 3 experiments ± SD; *P<0.05, **P<0.001. (B) OS cell invasion after 24-h IR treatment were examined by transwell chamber assays. The numbers of invading tumor cells that penetrated through Matrigel were counted and calculated in 5 high-magnification microscopy fields. Values represent the mean ± SD of 3 experiments; *P<0.05, **P<0.001.

Effects of low- or high-LET IR on orthotopic tumors in vivo

Based on these data, the therapeutic efficacy of high-LET radiation was assessed in vivo using an orthotopic mouse model (Fig. 6A). Significantly, neutron irradiation decreased tumor growth in mice as compared to that in gamma-ray-treated mice (Fig. 6B) with no visible signs of toxicity as evidenced by the lack of a difference in body weight (Fig. 6C). Additionally, H&E staining revealed that tumor from high-LET radiation-treated mice showed higher apoptosis rate (Fig. 6D).

Figure 6

The effects on orthotopic tumors in vivo treated with irradiation. (A) KHOS/NP cells were injected into the proximal tibia of 2 groups each containing 4 nude mice to generate an orthotopic tumor model. The dimensions of the leg (including the tumor) were measured every 7 days by X-ray analysis. Representative radiographs of the limb of a mouse at 0 and 6 weeks after tumor inoculation are shown. (B) Representative images of animal tumors at 6 weeks and a graph of tumor size against time are shown. The dimensions of the leg (including the tumor) were measured every 3–4 days and the volume was calculated. (C) Change in body weight at each time point relative to body weight at the time of treatment. n=3 per group, mean ± SD. (D) Tumors were excised and processed for immunostaining or hematoxylin and eosin (H&E) staining. Original magnification, ×100.

Discussion

Osteosarcomas (OSs) are primary malignant bone tumors identified by the production of osteoid or immature bone (1). These tumors generally exhibit a high potential for pulmonary metastasis and significant radioresistance (5–8). Based on this evidence, high-LET neutron and carbon ion beam radiations have been the preferred treatment modality for these patients. Preclinical evidence shows that the biological effects of IR depend on the quality-type and dose of radiation, as well as the cell or tumor type (24). High-LET radiation induces dense ionization along the particle track sufficient for highly localized DNA damage (25). Conversely, low-LET radiation beams are sparse, resulting in more diffuse, homogeneous dosing (25). Therefore, the biological effect of high-LET radiation is generally much higher than that of low-LET radiation at the same dose (26), generally, because high-LET radiation deposits most of its energy within one cell, resulting in more extensive DNA damage (27,28). Thus, high-LET radiation generates more complicated and varied cellular effects; however, the molecular mechanisms underlying high-LET radiation-induced cytotoxicity remain a topic of investigation.

Herein, we investigated the effects of high- and low-LET irradiation on the two OS cell lines. Notably, high-LET radiation was significantly more effective at inhibiting OS cell proliferation and inducing caspase-3/9 activation (Figs. 1 and 2). Additionally, an increase in AVOs was detected by acridine orange staining of lysosomes as well as conversion of LC3B-I into LC3B-II by immunoblotting in neutron treated cells. These results supported the induction of enhanced autophagy in response to neutron radiation in OS cells compared to that with gamma-ray radiation (Fig. 3). Our results also showed that high-LET radiation results in stable free radicals and more DSBs than that observed with gamma-ray radiation. Neutron irradiation also sensitizes OS cells by interfering with the NHEJ and HR pathways, thus limiting DSB repair in OS cells (Fig. 4). Finally, we studied the metastatic effect of IR treatment and found that neutron radiation effectively inhibited invasion and migration of OS cells (Fig. 5). These unique findings improve our understanding about the indirect effects of high-LET radiation and its clinical application to patients with OS.

Orthotopic models are essential for the preclinical evaluation of therapeutic agents and they are used for studying the pathobiology of tumor progression and metastasis. Accordingly, we examined the effects of each type of irradiation on an orthotopic mouse model of OS. Tumor measurements using caliper and H&E staining showed significantly smaller tumors with increased apoptosis in high-LET radiation-treated mice, consistent with our in vivo data (Fig. 6). However, only three medical centers worldwide use high-LET neuron radiotherapy to treat cancer, perhaps because of the difficulties in obtaining funding and regulatory approval. A potentially more viable alternative approach is to use other forms of high-LET radiation, such as carbon ion beams, which are widely used in both Japan and Europe. A previous study has shown similar RBE between neutron and carbon ion beams, but there are differences in the physical dose distribution and damage inflicted on normal tissues, which we intend to study further (10). Moreover, we believe that carbon ion beam radiotherapy results in a higher RBE than that with neutron beam causing less damage to normal tissues. Hence, carbon ion beam has proven to be a safe and effective modality to manage unresectable OS of the trunk, where it provides good local control and long-term functional results without ensuing morbidity (15,16).

Carbon ion high-LET radiation therapy has provided dramatic local control in Japanese hospitals and has become more popular in radiation treatment. Substantial research has shown that molecular mechanisms differ between high LET and low-LET radiation. These differences should be further investigated to delineate any potential rationale or clinical utility for low- versus high-LET radiation therapy, such as neutron or carbon beam treatment, in patients with OS.

In conclusion, our study revealed that as compared to low-LET gamma-ray radiotherapy, high-LET neutron radiotherapy provided a stronger therapeutic benefit by increasing OS cell apoptosis and DNA damage in vitro and in orthotopic mouse model in vivo, and thus, it provides further preclinical rationale for high-LET radiotherapy.

Acknowledgments

This study was supported by a National Research Foundation (NRF) of Korea grant (nos. NRF-2017R1D1A1B03028923) funded by the Korean Government (MSIP) and by a grant of the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by Ministry of Science, ICT, and Future Planning, Republic of Korea (1711045557;1711045538; 1711045554/50531-2017,50473-2017).

References

1 

Unni KK and Dahlin DC: Osteosarcoma: Pathology and classification. Semin Roentgenol. 24:143–152. 1989. View Article : Google Scholar : PubMed/NCBI

2 

Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, Ebb DH, Choy E, Raskin KA, Liebsch N, et al: Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 117:4522–4530. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Schwarz R, Bruland O, Cassoni A, Schomberg P and Bielack S: The role of radiotherapy in oseosarcoma. Cancer Treat Res. 152:147–164. 2009. View Article : Google Scholar

5 

Beck JC, Wara WM, Bovill EG Jr and Phillips TL: The role of radiation therapy in the treatment of osteosarcoma. Radiology. 120:163–165. 1976. View Article : Google Scholar : PubMed/NCBI

6 

DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE and Suit HD: Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 61:492–498. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Imai R, Kamada T, Tsuji H, Tsujii H, Tsuburai Y and Tatezaki S; Working Group for Bone and Soft Tissue Sarcomas: Cervical spine osteosarcoma treated with carbon-ion radiotherapy. Lancet Oncol. 7:1034–1035. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC and Gebhardt MC: Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 429:286–291. 2004. View Article : Google Scholar

9 

Lisle JW, Choi JY, Horton JA, Allen MJ and Damron TA: Metastatic osteosarcoma gene expression differs in vitro and in vivo. Clin Orthop Relat Res. 466:2071–2080. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Skarsgard LD: Radiobiology with heavy charged particles: A historical review. Phys Med. 14(Suppl 1): 1–19. 1998.

11 

Okayasu R: Repair of DNA damage induced by accelerated heavy ions - a mini review. Int J Cancer. 130:991–1000. 2012. View Article : Google Scholar

12 

Kamada T, Tsujii H, Blakely EA, Debus J, De Neve W, Durante M, Jäkel O, Mayer R, Orecchia R, Pötter R, et al: Carbon ion radiotherapy in Japan: An assessment of 20 years of clinical experience. Lancet Oncol. 16:e93–e100. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, et al: Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys. 44:201–210. 1999. View Article : Google Scholar : PubMed/NCBI

14 

Zhang W, Tanaka M, Sugimoto Y, Takigawa T and Ozaki T: Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow. Eur Spine J. 25(Suppl 1): 113–117. 2016. View Article : Google Scholar

15 

Matsunobu A, Imai R, Kamada T, Imaizumi T, Tsuji H, Tsujii H, Shioyama Y, Honda H and Tatezaki S; Working Group for Bone and Soft Tissue Sarcomas: Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 118:4555–4563. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Futamura G, Kawabata S, Siba H, Kuroiwa T, Suzuki M, Kondo N, Ono K, Sakurai Y, Tanaka M, Todo T, et al: A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy. Radiat Oncol. 9:2372014. View Article : Google Scholar : PubMed/NCBI

17 

Lee DH, Seo SH and Ji YH: Characteristics of radiation generated by BNCT irradiator of Hanaro nucleasr reactor. J Korean Soc Ther Radiol Oncol. 24:s1582006.

18 

Eom KY, Wu HG, Park HJ, Huh SN, Ye SJ, Lee DH and Park SW: Evaluation of biological characteristics of neutron beam generated from MC50 cyclotron. J Korean Soc Ther Radiol Oncol. 24:280–284. 2006.

19 

Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD, et al: An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 22:319–329. 2005. View Article : Google Scholar : PubMed/NCBI

20 

Song WS, Jeon DG, Cho WH, Kong CB, Cho SH and Lee SY and Lee SY: Spontaneous necrosis and additional tumor necrosis induced by preoperative chemotherapy for osteosarcoma: A case-control study. J Orthop Sci. 20:174–179. 2015. View Article : Google Scholar

21 

Kong CB, Byun BH, Lim I, Choi CW, Lim SM, Song WS, Cho WH, Jeon DG, Koh JS, Yoo JY, et al: 18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging. 40:728–736. 2013. View Article : Google Scholar : PubMed/NCBI

22 

McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI

23 

Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, Herceg Z, Wang ZQ and Schulze-Osthoff K: Activation and caspase-mediated inhibition of PARP: A molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 13:978–988. 2002. View Article : Google Scholar : PubMed/NCBI

24 

Goodhead DT, Thacker J and Cox R: Weiss Lecture. Effects of radiations of different qualities on cells: Molecular mechanisms of damage and repair. Int J Radiat Biol. 63:543–556. 1993. View Article : Google Scholar : PubMed/NCBI

25 

Goodhead DT: Energy deposition stochastics and track structure: What about the target? Radiat Prot Dosimetry. 122:3–15. 2006. View Article : Google Scholar

26 

Anderson RM, Marsden SJ, Wright EG, Kadhim MA, Goodhead DT and Griffin CS: Complex chromosome aberrations in peripheral blood lymphocytes as a potential biomarker of exposure to high-LET alpha-particles. Int J Radiat Biol. 76:31–42. 2000. View Article : Google Scholar : PubMed/NCBI

27 

Brenner DJ and Ward JF: Constraints on energy deposition and target size of multiply damaged sites associated with DNA double-strand breaks. Int J Radiat Biol. 61:737–748. 1992. View Article : Google Scholar : PubMed/NCBI

28 

Tanaka K, Gajendiran N, Endo S, Komatsu K, Hoshi M and Kamada N: Neutron energy-dependent initial DNA damage and chromosomal exchange. J Radiat Res (Tokyo). 40(Suppl): S36–S44. 1999. View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Kim EH, Kim M, Lee K, Sai S, Jeong YK, Koh J and Kong C: Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9. Int J Oncol 51: 1124-1134, 2017.
APA
Kim, E.H., Kim, M., Lee, K., Sai, S., Jeong, Y.K., Koh, J., & Kong, C. (2017). Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9. International Journal of Oncology, 51, 1124-1134. https://doi.org/10.3892/ijo.2017.4102
MLA
Kim, E. H., Kim, M., Lee, K., Sai, S., Jeong, Y. K., Koh, J., Kong, C."Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9". International Journal of Oncology 51.4 (2017): 1124-1134.
Chicago
Kim, E. H., Kim, M., Lee, K., Sai, S., Jeong, Y. K., Koh, J., Kong, C."Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9". International Journal of Oncology 51, no. 4 (2017): 1124-1134. https://doi.org/10.3892/ijo.2017.4102
Copy and paste a formatted citation
x
Spandidos Publications style
Kim EH, Kim M, Lee K, Sai S, Jeong YK, Koh J and Kong C: Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9. Int J Oncol 51: 1124-1134, 2017.
APA
Kim, E.H., Kim, M., Lee, K., Sai, S., Jeong, Y.K., Koh, J., & Kong, C. (2017). Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9. International Journal of Oncology, 51, 1124-1134. https://doi.org/10.3892/ijo.2017.4102
MLA
Kim, E. H., Kim, M., Lee, K., Sai, S., Jeong, Y. K., Koh, J., Kong, C."Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9". International Journal of Oncology 51.4 (2017): 1124-1134.
Chicago
Kim, E. H., Kim, M., Lee, K., Sai, S., Jeong, Y. K., Koh, J., Kong, C."Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9". International Journal of Oncology 51, no. 4 (2017): 1124-1134. https://doi.org/10.3892/ijo.2017.4102
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team